{"id":5304,"date":"2025-04-03T07:54:12","date_gmt":"2025-04-03T07:54:12","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solution&p=5304"},"modified":"2025-06-03T08:16:03","modified_gmt":"2025-06-03T08:16:03","slug":"esophageal-fibrosis","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/gastrointestinal-diseases\/esophageal-fibrosis\/","title":{"rendered":"Esophageal Fibrosis"},"content":{"rendered":"
\n \n
\n
\n
\n
\n

Biomarkers for eosinophilic esophagitis (EoE)<\/h2>\n \n\n <\/div>\n
\n

Esophageal fibrosis is characterized by excessive extracellular matrix deposition, primarily collagen accumulation within the lamina propria, leading to structural remodeling and impaired tissue function.<\/p>\n

Biomarkers reflecting collagen turnover provide a non-invasive approach to assessing disease activity<\/b>, monitoring fibrosis progression<\/b>, and evaluating the impact of therapeutic interventions <\/b>in EoE.<\/p>\n

By capturing dynamic changes in extracellular matrix remodeling, these biomarkers support drug development efforts, offering insights into target engagement, treatment response, and disease modification.<\/p>\n <\/div>\n <\/div>\n

\n \n Browse our gastroenterology portfolio \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Biomarkers for monitoring disease activity in EoE and Histological Remission in EoE<\/h2>\n \n\n <\/div>\n
\n

Biomarkers of neutrophil activity (nordicCPa9-HNE\u2122<\/a>), MMP-mediated collagen degradation (C3M<\/a>, nordicCTX-III\u2122<\/a>, C4M<\/a>, C6M<\/a>) and formation of type III and VI collagen (nordicPRO-C3\u2122<\/a>, nordicPRO-C6\u2122<\/a>) differentiate between patients with EoE and healthy subjects. These biomarkers offer a mechanistic assessment of ECM remodeling and neutrophil-driven inflammation in EoE, enabling patient stratification and disease monitoring. Notably, nordicCTX-III\u2122 reflects the MMP-mediated degradation of cross-linked type III collagen<\/b>, providing a direct measure of fibrosis resolution.<\/p>\n

Patients who fail to acheive histological remission have an overall elevation of MMP-mediated degradation of cross-linked type III collagen (nordicCTX-III\u2122) and increased net fibrolysis (balance between cross-linked type III collagen formation and degradation).<\/p>\n <\/div>\n

\n

Publications<\/h3>\n